The content on this site is intended for healthcare professionals only
Dr David Chang talks to ecancer at the 2013 WIN Symposium about a translational study downstream of the "Australian Pancreatic Cancer Genome Initiative".
Results from the study found that pancreatic cancer is a very heterogeneous disease, less than 2%, which, signals the need for multiple drugs in most patients treatment regimes. The study is now looking at patients who had significant responses to treatment in order to identify potential new targets.
Filmed in Partnership with the WIN Consortium
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer
Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer
Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer
Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepatocellular carcinoma
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
